AXSM has been the subject of a number of other reports. ValuEngine lowered shares of Axsome Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. HC Wainwright reaffirmed a buy rating and set a $15.00 price target on shares of Axsome Therapeutics in a report on Thursday, January 31st. Zacks Investment Research raised shares of Axsome Therapeutics from a sell rating to a hold rating in a report on Tuesday, February 5th. Cantor Fitzgerald raised their price target on shares of Axsome Therapeutics from $16.00 to $25.00 and gave the company an overweight rating in a report on Thursday, March 21st. Finally, LADENBURG THALM/SH SH reaffirmed a positive rating and set a $45.00 price target (up from $34.00) on shares of Axsome Therapeutics in a report on Monday, January 7th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Axsome Therapeutics presently has a consensus rating of Buy and an average price target of $28.25.
AXSM opened at $13.51 on Monday. The firm has a market cap of $449.61 million, a P/E ratio of -11.75 and a beta of 3.46. Axsome Therapeutics has a twelve month low of $1.94 and a twelve month high of $16.80. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 3.86.
In related news, Director Mark Coleman acquired 5,100 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was bought at an average cost of $12.18 per share, with a total value of $62,118.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Nick Pizzie acquired 5,400 shares of the firm’s stock in a transaction on Tuesday, March 19th. The shares were bought at an average cost of $12.58 per share, with a total value of $67,932.00. Following the completion of the acquisition, the chief financial officer now owns 36,340 shares in the company, valued at $457,157.20. The disclosure for this purchase can be found here. 34.30% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in AXSM. Millennium Management LLC bought a new position in shares of Axsome Therapeutics in the 4th quarter worth about $871,000. Barclays PLC bought a new position in shares of Axsome Therapeutics in the 4th quarter worth about $30,000. Bank of New York Mellon Corp bought a new position in shares of Axsome Therapeutics in the 4th quarter worth about $98,000. BlackRock Inc. lifted its position in shares of Axsome Therapeutics by 14.6% in the 4th quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock worth $181,000 after buying an additional 8,137 shares during the last quarter. Finally, Alethea Capital Management LLC lifted its position in shares of Axsome Therapeutics by 65.9% in the 4th quarter. Alethea Capital Management LLC now owns 908,429 shares of the company’s stock worth $2,562,000 after buying an additional 360,986 shares during the last quarter. 11.50% of the stock is owned by institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Further Reading: Stock Symbol
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.